Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles ...

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple ...

Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...

Please provide your email address to receive an email when new articles are posted on . Often regarded in oncology as a complementary diagnostic or early detection tool, liquid biopsy has moved into ...

Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease. Liquid biopsies, which require just a ...

For those with cancer, precision oncology promises better treatment plans. It is about allowing treatments to be selected on the basis of genetic signatures, which can reveal specific tumorigenic ...

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined with ...

Intuitive ISRG announced that the FDA has cleared the integration of mobile cone-beam CT (CBCT) imaging technology with its minimally-invasive, robotic-assisted bronchoscopy system, Ion Endoluminal ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is ...

Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity and ...

The trial of Theranos CEO Elizabeth Holmes for defrauding investors about the company’s blood tests highlights a more general reality: huge sums of money are being devoted to develop and promote ...